Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers.
Americans are drinking more, which puts them at risk of alcohol-related liver disease, heart disease, cancer and accidents.
Study finds estrogen alone and estrogen plus progesterone after menopause have opposite effects on breast cancer incidence.
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
These findings may indicate a new route to on-target therapeutic inhibition, a running goal for the academic and pharmaceutical communities.
The study followed up with people five to seven years after treatment, allowing the researchers to correlate blood factors with survival.
This technological advancement could help make up for a shortage in radiologists in the United Kingdom in particular.
Cancer mortality fell by 29% between 1991 and 2017, largely driven by a decline in lung cancer deaths.
Targeted therapies and immunotherapies may be effective against the bone metastases that grow from primary prostate cancers.
A new book advocates just that.
PARP inhibitor delays disease progression when used after successful chemotherapy.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
Researchers reached this conclusion using a cutting-edge form of genetic analysis.
Study focused on people who have exhausted available therapies but want to continue with treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.